Log In
BCIQ
Print this Print this
 

tralokinumab (CAT-354)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionHuman IgG4 mAb against IL-13
Molecular Target Interleukin-13 (IL-13)
Mechanism of ActionInterleukin-13 (IL-13) inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$115.0M

$1,000.0M


 Deals Details
Get a free BioCentury trial today